Who Responds Best to Sapropterin?
Sapropterin (Kuvan) works best in patients with tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU), particularly those with mild hyperphenylalaninemia or milder PAH gene mutations. About 20-50% of PKU patients show at least a 30% drop in blood phenylalanine (Phe) levels after a BH4 loading test, with higher responsiveness in those under age 6 at diagnosis and with baseline Phe between 360-600 μmol/L.[1][2]
How Do Doctors Test Responsiveness?
A supervised BH4 loading test measures Phe reduction over 24-48 hours after 20 mg/kg/day sapropterin dosing. Responders typically lower Phe by ≥30% without major dietary changes. Genetic testing of PAH mutations predicts response—milder mutations like R261Q or A300S correlate with better outcomes.[1][3]
Why Do Some PKU Patients Respond More Than Others?
Response ties to residual PAH enzyme activity. Mild PKU (classic or variant) patients retain enough enzyme for BH4 to boost Phe metabolism, unlike severe classic PKU where enzyme defects are profound. Infants and young children respond better due to less fibrosis in the liver.[2][4]
What About Non-PKU Conditions?
Sapropterin shows limited response in BH4 deficiencies (e.g., PTPS or DHPR defects), where neurotransmitter issues dominate over hyperphenylalaninemia. It's FDA-approved only for PKU hyperphenylalaninemia ≥6 years old, but off-label use in younger patients or segmental responsiveness occurs.[1][5]
Patient Age and Long-Term Response
Children under 4 respond in up to 62% of cases, dropping to 24% in adults. Long-term therapy sustains response in 90% of initial responders, allowing dietary Phe relaxation and better neurocognitive scores.[2][6]
[1]: FDA Label for Kuvan
[2]: Muntau et al., Mol Genet Metab 2011
[3]: Blau et al., J Inherit Metab Dis 2010
[4]: Vockley et al., Mol Genet Metab 2014
[5]: BioMarin Prescribing Information
[6]: Feldmann et al., Ann Neurol 2009